C. Müller-Tidow

Impact of daratumumab on stem cell collection in patients with AL amyloidosis

Autologous stem cell transplantation following high-dose melphalan is an effective consolidation therapy for the initial treatment of systemic AL amyloidosis. While quadruplet induction therapy involving daratumumab is the standard-of-care, its impact on stem cell yield has not been studied. Furthermore, the rela...

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Relapsed or refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge, with standard high‑dose cytarabine-based salvage regimens achieving complete remission (CR) rates of around 50%. In the phase 1/2 RELAX trial, adding venetoclax (VEN) to high‑dose cytarabine and mitoxantrone (HAM) was considered sa...

IDH3 regulates citrate homeostasis to control metabolic fitness and venetoclax resistance of AML stem cells.

Leukemic Stem Cell Subtypes Drive Distinct Niche Remodeling in Acute Myeloid Leukemia

Findings identify a specific LSC subtype as a source of niche-remodeling cues that shape specialized leukemia-supportive niches that shape specialized leukemia-supportive niches in vivo.

Divergent roles of interleukin-12p40 and interleukin-18 in severe fibrosing chronic graft-versus-host-disease, immunity, and post-transplant outcomes.

Among 14 cytokines, IL-12p40 and IL-18 emerged as divergent signatures, both were elevated in patients who later developed severe fibrosing cGvHD, but their clinical associations differed markedly.

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

SDRNAs are introduced as standalone regulatory effector molecules in healthy hematopoiesis and AML and proposed and characterized NUDT21, an important regulator of alternative polyadenylation and oncogenic gene expression, as a downstream target of sd3'-SNORD78 in AML.

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies tumor-reactive T cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control.